A Spanish team presents the first pharmacological treatment able to improve cardiac function in stiff-heart syndrome
Transthyretin-related cardiac amyloidosis has a poor prognosis, and untreated patients survive for an average of just 3 years
2023-05-20
(Press-News.org)
Transthyretin-related cardiac amyloidosis is a progressive disease characterized by the deposition of amyloid protein fibrils in the heart. Amyloid fibril deposition thickens and stiffens the heart walls, and the disease is also known as stiff-heart syndrome. The accumulation of amyloid fibrils causes heart failure, and patients suffer from fluid retention, fatigue, and arrhythmias. The disease can be caused by genetic mutations or related to aging. Prognosis is poor, and untreated patients survive for an average of just 3 years.
Now, the results of a study published in the The New England Journal of Medicine (NEJM) promise to radically alter the prospects of patients with this disease. The study was led by Dr. Pablo Garcia-Pavía, who heads the Inherited Cardiac Diseases Section at Hospital Universitario Puerta de Hierro and is a research scientist at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and within the Spanish cardiovascular research network (CIBERCV). Coinciding with the publication of the study, Dr. Pablo Garcia-Pavía has today presented the results of the first clinical trial with an amyloid-removing drug for the treatment of cardiac amyloidosis.
The study represents a major advance in the treatment of the disease. Although currently available treatments effectively prevent the accumulation of more amyloid fibrils and delay disease progression, they do not directly remove any amyloid protein already deposited in the heart.
Current treatment options include transthyretin-stabilizing therapy and measures to control associated cardiovascular complications. The only intervention currently able to restore cardiac function in this disease is heart transplantation.
The only drug approved to treat transthyretin-related cardiac amyloidosis is tafamidis, an oral transthyretin stabilizer. Tafamidis improves survival and reduces hospitalizations; however, it does not reverse disease symptoms that are already established.
The initial results of the trial, which included 40 patients in France, The Netherlands, Germany, and Spain and was coordinated by Dr. García-Pavía, show that the new drug is safe and appears to reduce the amount of amyloid protein deposited in the heart.
Developed by the Swiss company Neurimmune, the new medication is an antibody that binds to transthyretin amyloid protein. The antibody was first isolated from memory B cells obtained from healthy elderly individuals.
In the study, the antibody was used to stimulate the patients’ own defense systems, resulting in the elimination of cardiac amyloid fibrils. The antibody was administered to patients intravenously in progressively increasing monthly doses over a 12-month period.
“Patients who received higher antibody doses seemed to show a greater reduction in amyloid deposits in the heart and greater improvements in a range of cardiac parameters,” said Dr. García-Pavía.
The NEJM article concludes that the phase I proof-of-concept study demonstrates the safety of this treatment in patients and supports further clinical trials of this antibody.
Dr. García-Pavía is a world-leading expert on transthyretin-related cardiac amyloidosis and is the leader of the European Society of Cardiology guidelines on the diagnosis and treatment of this disease, which are followed worldwide.
His group at Hospital Puerta de Hierro is an international reference in the field and several years ago demonstrated that this disease, previously thought to be very rare, is one of the most frequent causes of heart failure in persons older than 65 years.
About the CNIC
The Centro Nacional de Investigaciones Cardiovasculares (CNIC), directed by Dr. Valentín Fuster, is dedicated to cardiovascular research and the translation of knowledge gained into real benefits for patients. The CNIC, recognized by the Spanish government as a Severo Ochoa center of excellence, is financed through a pioneering public-private partnership between the government (through the Carlos III Institute of Health) and the Pro-CNIC Foundation, which brings together 12 of the most important Spanish private companies.
END
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
2023-05-20
The Society for Cardiovascular Angiography & Interventions (SCAI) has named George Dangas, MD, PhD, Professor of Medicine (Cardiology), and Surgery, at the Icahn School of Medicine at Mount Sinai as its new President. He was appointed on Saturday, May 20, during the closing ceremonies at the SCAI 2023 Scientific Sessions in Phoenix. He is the first Mount Sinai cardiologist to hold this position and will serve as the 46th President of SCAI.
Dr. Dangas, also the Director of Cardiovascular Innovation at the Zena and Michael A. Wiener Cardiovascular Institute at Icahn Mount Sinai and Chief of Cardiology ...
2023-05-20
ARLINGTON, Va.—For Dr. Brett Seidle — the deputy assistant secretary of the Navy for Research, Development, Test and Engineering — the breakneck speed of current scientific progress and technological proliferation can be challenging, especially when the impact of new technologies on civilian and military realities transcends national borders.
While giving the keynote address at the recent Specialized Inter-American Naval Conference on Science, Technology and Innovation (SIANC-ST&I) in Orlando, Florida, Seidle identified several scientific disciplines that have developed into ...
2023-05-20
UNIVERSITY PARK, Pa. — Reduce fossil fuel use and air quality will improve, right? It might not be as straightforward as it appears, according to a Penn State-led research team. They explored almost 30,000 simulated future scenarios and found that some climate mitigation efforts could lead to harmful health impacts in certain geographic areas.
Their results were published today (May 18) in Nature Sustainability.
“In general, reducing fossil fuel use is good for climate mitigation and good for cleaning up the air, and the modeling studies have always found health benefits from climate mitigation,” said corresponding ...
2023-05-20
New research presented at this year’s European Congress on Obesity in Dublin, Ireland shows that patients treated with the obesity drug semaglutide have a decreased cardiovascular risk score after one year of use. The study is by Dr Andres Acosta and Dr Wissam Ghusn, Precision Medicine for Obesity Program at the Mayo Clinic, Rochester, MN, USA and colleagues.
Obesity is a major risk factor for the development of abnormal blood fat levels, type-2 diabetes mellitus (T2DM), high blood pressure, and obstructive sleep apnoea. These comorbidities are associated with an increased risk of cardiovascular disease (CVD) that represents ...
2023-05-20
New research presented at this year’s European Congress on Obesity (ECO2023, Dublin, 17-20 May) shows that the obesity drug semaglutide is effective for weight loss in a multicentre, 1-year-long real-world study. The study is by Dr Andres Acosta and Dr Wissam Ghusn, Precision Medicine for Obesity Program at the Mayo Clinic, Rochester, MN, USA and colleagues.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the most recently FDA-approved anti-obesity medication. It has shown significant weight loss outcomes in multiple long-term randomised clinical trials and short-term real-world studies. However, little is known about ...
2023-05-20
Teenagers living with obesity who say hunger is preventing them from losing weight (hunger-barrier ALwO) perceive their weight more negatively and worry about it more than youngsters who don’t see hunger as an obstacle, new research being presented at the European Congress on Obesity (ECO) in Dublin, Ireland (17-20 May) shows.
The international study also found that hunger-barrier ALwO are more likely to be female and more likely to say their weight makes them unhappy and leads to them being bullied. They are also more likely to be actively trying to lose weight.
Dr Bassam Bin-Abbas, of the Department of Paediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, ...
2023-05-20
New research being presented at this year’s European Congress on Obesity (ECO) in Dublin, Ireland (17-20 May) suggests that glucocorticoid levels (a class of steroid hormones secreted as a response to stress) present in the hair of individuals may indicate which of them are more likely to suffer from cardiovascular diseases (CVD) in the future.
“There is a tremendous amount of evidence that chronic stress is a serious factor in determining overall health. Now our findings indicate that people with higher long-term hair glucocorticoid ...
2023-05-20
NERC has invested £25 million in a host of high risk, high reward research projects to tackle critical environment challenges.
The 44 projects cover the full spectrum of environmental science including geology, atmospheric science, biodiversity and ecology.
The research will, for example:
improve our understanding of volcanic activity such as eruptions a lava flows
age the Earth’s solid inner core
investigate historic mass extinction events
predict future changes to carbon ...
2023-05-20
The make-up and volume of gut bacteria in toddlers at 3.5 years old is predictive of body mass index (BMI) at age 5, irrespective of whether they are born prematurely or not, according to new research, being presented at this year’s European Congress on Obesity (ECO) in Dublin, Ireland (17-20 May).
The findings also identified differences in the bacteria that colonise the gut seen in adults living with obesity, suggesting that changes in the gut microbiota that predispose to adult obesity begin in early childhood.
The make-up of the gut microbiota grows and changes in the first few months and years of life and ...
2023-05-20
Scientists are to deploy a network of microphones in the Amazon rainforest to listen and measure the numbers and species of birds, insects and other wildlife.
The use of ‘ecoacoustics’ forms part of RAINFAUNA - a £1 million study by an international team of researchers led by scientists at Lancaster University that will provide the first large-scale understanding of how humans are affecting the animals that call tropical forests home.
Tropical forests are under threat. In the Amazon, at least 17% of primary ...
LAST 30 PRESS RELEASES:
[Press-News.org] A Spanish team presents the first pharmacological treatment able to improve cardiac function in stiff-heart syndrome
Transthyretin-related cardiac amyloidosis has a poor prognosis, and untreated patients survive for an average of just 3 years
